Aims This review provides an up-to-date curated source of information on alcohol, tobacco and illicit drug use and their associated mortality and burden of disease. Limitations in the data are also discussed, including how these can be addressed in the future. Methods Online data sources were identified through expert review. Data were obtained mainly from the World Health Organization, United Nations Office on Drugs and Crime and Institute for Health Metrics and Evaluation. Results In 2015, the estimated prevalence among the adult population was 18.4% for heavy episodic alcohol use (in the past 30 days); 15.2% for daily tobacco smoking; and 3.8, 0.77, 0.37 and 0.35% for past-year cannabis, amphetamine, opioid and cocaine use, respectively. European regions had the highest prevalence of heavy episodic alcohol use and daily tobacco use. The age-standardized prevalence of alcohol dependence was 843.2 per 100 000 people; for cannabis, opioids, amphetamines and cocaine dependence it was 259.3, 220.4, 86.0 and 52.5 per 100 000 people, respectively. High-income North America region had among the highest rates of cannabis, opioid and cocaine dependence. Attributable disability-adjusted life-years (DALYs) were highest for tobacco smoking (170.9 million DALYs), followed by alcohol (85.0 million) and illicit drugs (27.8 million). Substance-attributable mortality rates were highest for tobacco smoking (110.7 deaths per 100 000 people), followed by alcohol and illicit drugs (33.0 and 6.9 deaths per 100 000 people, respectively). Attributable age-standardized mortality rates and DALYs for alcohol and illicit drugs were highest in eastern Europe; attributable age-standardized tobacco mortality rates and DALYs were highest in Oceania. Conclusions In 2015 alcohol use and tobacco smoking use between them cost the human population more than a quarter of a billion disabilityadjusted life years, with illicit drugs costing further tens of millions. Europeans suffered proportionately more, but in absolute terms the mortality rate was greatest in low-and middle-income countries with large populations and where the quality of data was more limited. Better standardized and rigorous methods for data collection, collation and reporting are needed to assess more accurately the geographical and temporal trends in substance use and its disease burden.
INTRODUCTION
Alcohol, tobacco and illicit drug use are major global risk factors for disability and premature loss of life [1] . Their health burden is accompanied by significant economic costs, namely expenditure on health care and law enforcement, lost productivity and other direct and indirect costs, including harm to others [2] . Estimating the prevalence of use and associated burden of disease and mortality at country, regional and global levels is critical in quantifying the extent and severity of the burden arising from substance use. This knowledge should inform allocation decisions by governments, policymakers and funding bodies about service provision and policy and assist in evaluations of the impact of policies [3] . These estimates must be developed rigorously, updated regularly and be geographically comprehensive to quantify and detect change in indicators over time.
There are various research groups that regularly compile estimates of the global prevalence of substance use, dependence and related disability and mortality. It is useful to collate these collections to provide an overall global picture of the distribution of substance use and associated mortality and burden of disease and to highlight key gaps in evidence. Indeed, these data are critical to monitoring progress towards the Sustainable Development Goals [4] , particularly those requiring quantification of the prevalence of substance use and dependence to calculate appropriate treatment and intervention coverage. This review is part of an ongoing series [5] which has two purposes, to: (i) curate recent estimates of the prevalence of use, dependence, mortality and burden of disease associated with alcohol, tobacco and illicit drugs at country, regional and global levels and (ii) comment on the availability and quality of existing data collections and identify challenges in estimating and comparing substance use and related burden geographically and temporally. For the purpose of this review, illicit drug use was defined as use of a substance where consumption has been prohibited by international drug control treaties except for medical purposes [3] . For illicit drugs, we focused upon use of cannabis, noting that policy regarding cannabis use and supply varies in some countries, (e.g. United States, the Netherlands [6] ), methamphetamine, cocaine, as well as extra-medical opioid use, (i.e. use that is without a prescription or not as directed by a doctor [7] ). We also briefly considered estimates related to use of new psychoactive substances (NPS; see Box 1 for details about NPS).
METHODS

Design
We identified online data sources on alcohol, tobacco and illicit drug use, dependence and attributable burden of disease and mortality through web searches and e-mail consultations with experts in the epidemiology of substance use. This review focused upon data collections at the global level, which also disaggregate estimates at country and/or regional levels. These collections are held mainly by the following organizations: World Health Organization (WHO); United Nations Office on Crime and Drugs (UNODC); and the Institute for Health Metrics and Evaluation's (IHME) Global Burden of Disease (GBD) study 2015. Details of data collections and reporting by these organizations (including links to downloadable data) are provided in Table 1 , and regional classifications of countries for each organization are provided in Supporting information, Appendix S1. The section below overviews the indicators of interest, and data sources used, for the present paper. It should be noted that these organizations use different approaches for identifying source data and modelling estimates, and thus comparison of estimates from different organizations may not be valid (see Discussion for further details).
Prevalence of substance use
Indicators of interest comprised the annual prevalence of alcohol, tobacco and illicit drug use (including NPS and injecting drug use) among the adult population in 2015.
Estimates of the prevalence of alcohol use for 2015 for the adult population (aged ≥ 15 years) by region and globally were obtained from the WHO Collaborating Centre for Addiction and Mental Health (CAMH) for validation and later inclusion into the Global Status Report on Alcohol and Health 2018 and the Global Information System on Alcohol and Health [14] .
Global and regional estimates of the age-standardized prevalence of daily tobacco smoking in the adult population were obtained from the GBD study 2015 [15] . This indicator underestimates total prevalence in countries such as the United States, where non-daily smoking is relatively common but still represents substantial use.
Figures on non-daily smoking were not available for many countries. This indicator also does not include non-smoked forms of tobacco (which is common in many parts of the world). Global and regional estimates of the annual prevalence of illicit drug use and NPS use among the adult population (age 15-64 years) in 2015 were obtained from the UNODC World Drug Report 2017 [10] , with reference to the European School Survey Project on Alcohol and Other Drugs 2015 report [11] . Estimates of the prevalence of injecting drug use for 2015 in the adult population (age 15-64 years) were obtained from the UNODC World Drug Report 2017 [10] , the GBD study 2015 [15] and from a recent multi-stage systematic review of peerreviewed and grey literature on the global epidemiology of injecting drug use [16] .
Box 1: Monitoring new psychoactive substance (NPS) use and harms
• New psychoactive substances (NPS) are substances which have similar acute psychoactive effects to established illicit drugs but are not controlled under international drug controls [8] .
• There has been a growth in the number of NPS notified to the European Union (EU) early warning system for the first time (see figure below), although the rate growth in 2016 declined [9] .
• This expanding production makes monitoring the prevalence of NPS use challenging, and there are substantial gaps in knowledge about the extent of NPS use. The United Nations Office on Drugs and Crime (UNODC) World Drug Report 2017 [10] has listed estimates of prevalence of NPS use for only 15 countries since 2006.
• UNODC's country-level estimates of past year NPS use [10] are typically < 1% of the sampled population. They are derived mainly from adolescent and young adult samples and are typically specific to a NPS class (e.g. piperazines) or substance (e.g. mephedrone) [10] . • Higher rates have been reported from the European School Survey Project on Alcohol and Other Drugs 2015 [11] , with 3% of 15-16-year-old European school students reporting any NPS use at least once in the past 12 months, and higher prevalence in Estonia and Poland (8%).
• Reported prevalence may be low among the general population, but needs to be considered in the context of considerable epidemiological challenges in this area, which include problems with the definition of NPS and a lack of standardized measurement tools.
• Indeed, self-report data are becoming less reliable for assessing drug groups such as NPS, where consumers may be unaware or misinformed of the substance they have consumed. Various indicators can be monitored and triangulated to better quantify NPS use and associated harms, e.g. ambulance attendances, emergency department presentations, poisons and toxicology data, and law enforcement drug seizures [12] .
• Key to monitoring NPS is early detection of NPS entering the market which have the capacity to cause substantial harm to the consumers, as illustrated by the recent emergence of highly potent synthetic opioids [9] .
• Although NPS comprise a minority of the drugs for sale on surface and darknet websites [13] , monitoring these sites can yield timely and regular data on changes in the NPS market.
Number and categories of new psychoactive substances notified to the EU Early Warning System for the first time, 2009-15, adapted from [9, 12, 13] 
Prevalence of substance dependence
Indicators of interest comprised the prevalence of pastyear alcohol, tobacco and illicit drug dependence among the adult population in 2015. Modelled estimates of global and regional all-age number and age-standardized rate (per 100 000 people) of past-year dependence on alcohol, amphetamine, cannabis, cocaine and opioids were obtained from the GBD study 2015 by region [15] . Estimates of smoked tobacco dependence are not modelled in the GBD study. Daily smokers have a very low probability of successful quitting in any given attempt [17] , and so daily smoking was considered indicative of a significant level of dependence in the current study. Substance dependence was defined according to the Diagnostic and Statistical Manual of Mental Disorders IV edition [18] and the International Classification of Diseases 9th or 10th editions [19] . We used this rather than 'substance use disorder' as defined in DSM 5th edition, because that is the most commonly available indicator globally.
All-cause substance-attributable mortality
Estimates of smoked tobacco, alcohol and illicit drug allcause attributable mortality from all disease and injuries were obtained from the GBD study 2015 [15] . The regional and global number of all-age attributable deaths and age-standardized death rate (per 100 000) are presented.
Substance attributable burden of disease
Disease burden caused by alcohol use, tobacco smoking and illicit drug use as risk factors are presented. Burden of disease was presented for substance use attributable disability-adjusted life years (DALYs), which are the sum of years of life lost (YLLs) to premature mortality and years of life lived with disability (YLDs). Modelled estimates of global and regional attributable DALYs (all-ages) and agestandardized (per 100 000 people) attributable DALYs for alcohol, smoked tobacco and illicit drugs for the adult population were obtained from the GBD study 2015 [15] . We also obtained estimates of the serological prevalence of HIV and hepatitis C virus (HCV) antibody among the adult population (age 15-64 years) who inject drugs from the UNODC World Drug Report 2017 [10] and from a recent multi-stage systematic review of peer-reviewed and grey literature on the global epidemiology of injecting drug use [16] .
Analyses
Modelled estimates are presented as obtained from source documents. Uncertainty intervals (UI) are presented where available to indicate the uncertainty range around the estimate; the way in which these intervals were generated differs across data collections (see details in Table notes) .
RESULTS
Substance use
Globally, CAMH [14] f Life-time and past 12-month abstainers are the proportion of adults (15+ years) in a given population who have not consumed any alcohol during their life-time or past 12 months, respectively, assessed at a given point in time (computed from the total number of participants (15+ years) responding to the corresponding question in a given survey). Former drinkers is the proportion of adults (15+ years) in a given population who did not consume alcohol in the last 12 months, but who did previously, assessed at any given point in time (computed from the total number of participants (15+ years) responding to the corresponding question in a given survey).
g Data on daily tobacco smoking were extracted from the GBD study 2015 [15] . In the GBD study, 95%
uncertainty intervals (UIs) are derived from 1000 draws from the posterior distribution of each step in the estimation process. The UIs capture uncertainty from multiple modelling steps and from sources such as model estimation and model specification.
school students) reported use of specific NPS in the past year (see Box 1 for discussion of limitations and future directions of monitoring NPS use).
In the UNODC World Drug Report 2017 [10] it was estimated that 0.25% (0.18, 0.36) of the adult population aged 15-64 years reported injecting drug use in 2015, equating to 11.8 million (8.6, 17.4) people (Table 3) . In contrast, a recent global systematic review [16] estimated that 0.33% (0.21, 0.49) of the adult population reported injecting drug use in the past year in 2015. This equates to 15.6 million (10.2, 23.7) people (Fig. 2) .
Substance dependence
Globally, alcohol dependence was the most prevalent substance of dependence ( [10] , and estimates here were as reported by UNODC on 6 September 2017. The annual prevalence rate is defined as the number of people who have consumed the drug at least once during the 12 months prior to the study, expressed as a percentage of the population aged 15-64 years, as provided by the United Nations Population Division for 2015. Estimates refer to unsanctioned use; that is, where possession and/or supply is illegal or prescription medications are being used in an unsanctioned way. Estimates are derived from country-level annual report questionnaire data and other official sources. Subregional estimates are computed where prevalence estimates for at least two countries covering at least 20% of the population were available;
À denotes that an estimate was not available. Uncertainty ranges were calculated using UNODC's regional and global estimation methods, taking the 10th percentile of the lower bounds of the uncertainty ranges and the 90th percentile of the upper bounds of the uncertainty ranges, based on the 90% confidence intervals or best available estimates available for countries with data within the regions (see [31] for further details of calculation uncertainty ranges). Substance use attributable mortality and burden of disease Globally, the highest age-standardized rates of mortality were for smoked tobacco as a risk factor at 110.7 (101.0, 120.3) per 100 000 deaths, compared to 33.0 (28.0, 37.7) and 6.9 deaths 6.9 (6.1, 7.6) per 100 000 people in 2015 for alcohol and illicit drugs, respectively ( (14.0, 19.9) , of which 12.9 (9.9, 14.1) were 
DISCUSSION
Main findings
Alcohol use and tobacco smoking are far more prevalent than illicit substance use globally and in most regions. Global estimates suggest that one in five adults report at least one occasion of heavy episodic alcohol use in the past month, increasing their risk of acute harm, e.g. injury [14] . Nearly one in seven adults were estimated to engage in daily tobacco smoking, increasing their risk of 12 types of cancer, non-malignant respiratory diseases, cardiovascular disease and a wide array of other chronic health conditions [21] . In contrast, use of illicit drugs was far less common. Fewer than one in 20 people were estimated to use cannabis in the past year, and much lower estimates were observed for amphetamines, opioids and cocaine.
The majority of the health burden from substance use was attributable to tobacco smoking (the most prevalent substance) and the smallest attributable to use of illicit drugs. There was substantial geographical variation in these estimates and several caveats (discussed below) need to be borne in mind when interpreting these data.
Data availability
Certain countries and regions (e.g. Africa, Caribbean and Latin America, Asia regions) have limited or no data on substance use and associated health burden. These are typically low-or middle-income countries that frequently have punitive drug policies, and may experience serious political and social unrest. These countries often warrant enhanced monitoring because they are at risk of rapid escalation in substance use and related health burden. For example, a recent review found evidence of injecting drug use in 23 countries in sub-Saharan Africa, where it had not been documented previously [16] . However, only seven of the 37 countries that had evidence of injecting drug use in the sub-Saharan Africa region offered needle-syringe programmes, and only eight offered medication-assisted Data in the table above were extracted from the GBD study 2015 [15] . Age-standardized rates (age SDR) is the rate per 100 000 people, estimated using the GBD world population age standard. Substance dependence was defined according to the Diagnostic and Statistical Manual of Mental Disorders [18] and the International Classification of Diseases [19] . Data are derived from systematic review of peer-review and grey literature, including estimates from studies published since 1980, and data were modelled using DisMod-MR 2.1; 95% uncertainty intervals (UIs) were derived from 1000 draws from the posterior distribution in the estimation process. Data were available for 180 countries for alcohol dependence, 55 countries for amphetamine dependence, 151 countries for cannabis dependence, 43 countries for cocaine dependence and 32 studies for opioid dependence. In the GBD study, 95% UIs are derived from 1000 draws from the posterior distribution of each step in the estimation process. The UIs capture uncertainty from multiple modelling steps and from sources such as model estimation and model specification.
a Grouping of countries reflect GBD classification. treatment for opioid dependence. The coverage of interventions, where they were offered, was very low [22] . These countries face the risk of a rapid escalation in HIV infection among people who inject drugs. In countries where no data have been collected, an alternative is to impute prevalence. Imputed prevalence can be based on prevalence in neighbouring countries and country-level predictors. The GBD study uses disease modeling-Metaregression DisMod [23] to fill gaps where data are incomplete to produce prevalence and disease burden estimates for each disease cause, age group, sex, country and year. There are, however, substantial uncertainties in these modelled estimates. This can be reduced only as better epidemiological evidence becomes available.
Data quality and estimation
The quality of estimates is often poor when data are available. For example, there is greater geographical coverage in estimates of alcohol use because consumption can be monitored more effectively via surveys [24] , and taxation, production, import and export data are available to produce estimates of consumption [25] . However, unrecorded consumption, which is estimated to account for approximately 25% of all alcohol use globally, introduces marked measurement error [26] . Similarly, prevalence of daily tobacco smoking obtained from the GBD study 2015 did not include non-daily smoking and abstinence among those who have ever smoked; see [27] for further details of estimation of prevalence of tobacco smoking in GBD, which varies considerably across countries [28] . Indeed, a review of 16 countries showed a substantially lower rate of abstinence among people who formerly smoked tobacco daily in China, India, Egypt, Russia and Bangladesh (< 20%) relative to similar indicators in the United Kingdom, United States, Brazil and Uruguay (> 35%) [28] . Further, the estimates of prevalence of daily tobacco smoking did not include smokeless tobacco product use, as well as the use of e-cigarettes and heat-not-burn tobacco products. Given the emerging trends of non-cigarette products, it would be useful to have these modelled separately to monitor changes in prevalence over time for different types of tobacco products in the population.
The need to measure progress towards various targets for improving global health has facilitated progress in standardizing epidemiological indicators throughout studies [4, 29] . Nonetheless, there is no gold-standard method for estimating how many people use or are dependent upon alcohol, tobacco and illicit drugs, and no single method is ideal for all substances in all national contexts (Table 6 ). General population surveys rely on honest self-report of substance use. Marginalized groups with high levels of problematic substance use (e.g. prisoners, homeless people), or those living in countries where substance use is forbidden or stigmatized for religious or cultural reasons, are often excluded from such surveys. This leads to underestimates of the prevalence of the most stigmatized and harmful forms of substance use in ways that can vary Table 6 Estimating the size of the population that uses drugs.
Method Summary Limitations
Population surveys Representative sample is directly asked about drug use in a specified time-period Population size is modelled based on reports from participants in general population samples on the number of people in the target population who are in their personal social network Assumes that participants are aware of their social contacts being members of the target population and that members of the target population have a personal network of the same size as the general population [32] Multiple parameter evidence synthesis Bayesian synthesis of all available evidence, including potential biases affecting such evidence, to give an estimate that is consistent with all evidence and internally validated Complex relative to other methods and technically difficult to implement [32] geographically [3] . Indirect methods of estimating prevalence for more stigmatized forms of substance use (e.g. multiplier, capture-recapture, network scale-up) may be biased by data limitations, e.g. dependencies between data sources in capture-recapture studies [30] . Even the use of multiple indirect methods to estimate a single population size may not remedy biases in individual methods, as estimates may be inconsistent with each other, and simply averaging across estimates is not guaranteed to reduce bias [31] . Multi-parameter evidence synthesis addresses these limitations by triangulating all available evidence (including estimates of potential biases), but this approach is complex and technically challenging to implement [32] .
Differences in estimates also occur throughout data collections. For example, we reported estimates of global prevalence of injecting drug use from the UNODC World Drug Report 2017 0.25% (0.18, 0.36) [10] and a recent systematic review of peer-review and grey literature 0.33% (0.21, 0.49) [16] . In this instance, data sources used within each country to model prevalence were mostly the same and the uncertainty intervals overlapped, suggesting that prevalence lies somewhere within this range. However, the various collections are based on different search processes, criteria for source data inclusion and modelling approaches to derive global estimates. For example, crude data included as input for analysis in the GBD study 2015 were extracted from national data systems (e.g. vital statistics, disease registries, demographic surveillance systems), surveys (e.g. household surveys), clinical informatics (e.g. disease notification data, health service encounter data such as hospital in-patient episodes), grey literature [e.g. government/country reports, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)] and scientific literature, e.g. peer-reviewed papers containing healthrelated data [33] . The GBD study 2015 used disease modeling-Metaregression DisMod [23] , which checks internal consistency of existing estimates and fills gaps where data are incomplete to produce prevalence and disease burden estimates [34] . The GBD study 2015 also produced UIs which capture uncertainty from sample sizes of data sources, multiple modelling steps and from sources such as model estimation and model specification [20] . In contrast, the UNODC [35] derive data primarily from the Annual Reports Questionnaire (ARQ) completed by Governments of Member States each calendar year. Estimates are computed using various adjustments, and imputation for countries where data are missing based on countries in the same subregion. Upper and lower uncertainty range estimates are calculated at a 90% confidence interval among those aged 15-64 years; see [35] for further details of methods. However, global estimates from these organizations cannot be combined to identify the 'true' prevalence. Instead, we require the collection of high-quality data and interrogation of estimation methods to maximize their consistency.
Quantifying burden of disease and mortality
There must be direct evidence that exposure to alcohol, tobacco or illicit drugs is (to some degree) linked to a health outcome before any such injury or disease is quantified within attributable burden [36] . This is challenging, because risk can vary according to substance type, frequency and quantity of use, route of administration, and concomitant use of substances. The quality of epidemiological data also varies across substances, with stronger evidence for the effects of alcohol and tobacco than for illicit drugs. The GBD study [15] represents one effort to review, synthesize and evaluate the weight of evidence regularly to support attribution (wholly or in part) to use of the specific substance (see Supporting information, Appendix S3 for disease conditions included in attributable burden quantification in 2015).
There are a number of injury and disease categories where there is growing epidemiological evidence for causality, (e.g., depression attributable to alcohol and drugs [37] ) and biologically plausible attribution based on the pharmacodynamics of alcohol, tobacco and illicit drugs. These factors suggest that we underestimate the true burden of alcohol, tobacco and especially illicit drug use. The degree of underestimation will be reduced by high-quality studies on the acute and chronic causal effects of substances (e.g. emergency room studies, autopsy studies and, in particular, longitudinal cohort studies with record linkage to administrative health data) and comprehensive systematic reviews of these studies that assess the relative risk for incidence of injuries and diseases.
There are also limitations in the mortality data modelled in the GBD study. Data on causes of death are dependent upon the quality of death certificates, verbal autopsies and the study's method for code reassignment to probable cause of death when deaths are assigned codes that cannot be the underlying causes of death. For example, recent US research has shown corrected opioid-related mortality counts and rates 21-35% higher than original estimates from 1999-2015 when missing data on the specific opioid underlying drug poisoning deaths were imputed [38] . Future research on the validity of code redistribution methods (e.g. for drug overdose deaths) and higher-quality original data (including integrating verbal autopsies with vital statistics) will improve mortality estimates [39] . Further details on the limitations on the cause of death modelling method in the GBD study are published elsewhere [40] .
It is important to acknowledge that estimates of burden quantify only the health consequences primarily for the consumer and largely omit effects on others (with some exceptions, e.g. effects of fetal alcohol exposure, second-hand smoking). They also do not quantify broader social and economic burdens imposed by substance use.
Measuring trends
We did not investigate trends over time in substance use and related burden in this review, although trend analyses have been conducted in other publications, e.g. [41] . The quality of trend data is considerably poorer for illicit drugs than for alcohol and tobacco consumption, where many countries have high-quality epidemiological data on use and consumption data over many years.
To assess change in substance use and burden validly we need national surveillance systems that have been conducted regularly and consistently over time in their definition of indicators, data collection methods, sampling and geographical coverage. Guidelines on epidemiological indicators, e.g. [28] , and methods of measuring indicators, e.g. [42] , will facilitate use of consistent approaches over time and between countries. The ability to implement regular studies are limited by the significant costs and resources needed to establish and regularly conduct surveillance studies, particularly population surveys. Improved data collection and estimation may mean that apparent temporal changes reflect variation in methods rather than 'true' changes in the indicator of interest.
One potentially useful new approach, particularly for illicit drug use, is to monitor levels of drug metabolites and residues in wastewater. Wastewater analyses can provide trends in total population-level consumption of licit and illicit drugs, as indexed by a population-normalized load of drug residue within the catchment area of wastewater treatment plants typically mg/1000 people/day [43, 44] . Direct inferences about changes in the number of people who use drugs or their patterns of use cannot be made using these data, but it may provide objective information that is not subject to under-representation of population groups or self-report bias as with surveys. Wastewater analysis may help to identify the full spectrum of pharmacological compounds consumed, including low prevalence drugs (e.g. NPS) and substances that are unknowingly consumed, e.g. mephedrone where sold as MDMA [44] . Further, wastewater can be sampled and tested regularly in near real-time. Various surveillance systems globally [44] now include wastewater data alongside survey results and indirect statistical methods to monitor spatiotemporal trends.
CONCLUSIONS
Alcohol, tobacco and illicit substance use are important contributors to global burden of morbidity and mortality. Tobacco and alcohol are used more commonly and make larger contributions to disease burden that illicit drugs, we know the latter's burden has greater issues of underestimation because of greater limitations of data availability and quality. Regular compilations of global data on geographical variations in prevalence of substance use and disease burden, such as this, may encourage the improvements in data and methods required to produce better future estimates.
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